3 years 1.18
Extreme 1.18
4.02
5 years 1.05
Extreme 1.05
11.78
10 years 1.05
Extreme 1.05
21.44
Manager TitleAgeSince
Chief Executive Officer 61 10/03/2023
Director of Finance/CFO 54 17/07/2025
Corporate Secretary - 17/07/2025
Date Insider Type Main position Quantity % Market Cap. Importance
17/07/25 Issuer sale

Director

15,53,657 5.8540%
17/07/25 Issuer sale

Chief Financial Officer

1,58,488 0.5972%
17/07/25 Issuer sale

Chief Technology Officer

3,51,145 1.3231%
Change 5-day change 1-year change 3-year change Capi.($)
+3.75%-.--% - - 11Cr
+3.46%+6.83%+31.94%+44.25% 26TCr
+3.03%+6.46%+12.32%+10.54% 16TCr
+1.81%+3.00%-1.78%+56.64% 15TCr
+2.65%+5.00%-54.83%-10.86% 6.4TCr
+1.91%+4.58%+20.80%+24.47% 5.08TCr
+1.87%+6.29%-12.62%-12.73% 5.09TCr
+0.89%+4.39%+25.71%+58.85% 4.95TCr
+5.27%+9.90%+8.93%+44.85% 5.07TCr
+1.73%+3.50%+33.62%+75.82% 4.36TCr
Average +2.23%+4.66%+7.12%+32.42% 9.79TCr
Weighted average by Cap. +2.02%+4.04%+11.42%+34.13%
Logo ICAD
iCAD Inc is a United States‑based company. The Company develops artificial intelligence solutions designed to support healthcare providers in the detection and diagnosis of cancer. The company focuses on providing clinically proven AI technologies that assist medical professionals in identifying cancer earlier, improving diagnostic accuracy, and enhancing workflow efficiency. Its solutions include platforms for cancer detection, breast density assessment, and risk evaluation, enabling clinicians to analyze medical images and support patient care decisions. The company leverages advanced data, clinical evidence, and AI‑driven technologies to deliver tools that integrate into existing healthcare systems and assist in screening and diagnostic processes across global markets.
Employees
66
  1. Stock Market
  2. Stocks
  3. ICAD Stock